اخبار و اعلانات

 آمار

تعداد نشریات418
تعداد شماره‌ها9,991
تعداد مقالات83,502
تعداد مشاهده مقاله76,929,481
تعداد دریافت فایل اصل مقاله53,999,280
Shi, Xin, Gao, Hongli, Zhao, Qian, Zhuang, Mengqi. (1400). Clinical efficacy and safety of inhibitors of programmed cell death protein 1 and its ligand in postoperative chemotherapy for advanced colorectal cancer. نشریه علمی پژوهشی دانشگاه آزاد اسلامی, 13(1), -. doi: 10.47176/IJIC.13.1.3
Xin Shi; Hongli Gao; Qian Zhao; Mengqi Zhuang. "Clinical efficacy and safety of inhibitors of programmed cell death protein 1 and its ligand in postoperative chemotherapy for advanced colorectal cancer". نشریه علمی پژوهشی دانشگاه آزاد اسلامی, 13, 1, 1400, -. doi: 10.47176/IJIC.13.1.3
Shi, Xin, Gao, Hongli, Zhao, Qian, Zhuang, Mengqi. (1400). 'Clinical efficacy and safety of inhibitors of programmed cell death protein 1 and its ligand in postoperative chemotherapy for advanced colorectal cancer', نشریه علمی پژوهشی دانشگاه آزاد اسلامی, 13(1), pp. -. doi: 10.47176/IJIC.13.1.3
Shi, Xin, Gao, Hongli, Zhao, Qian, Zhuang, Mengqi. Clinical efficacy and safety of inhibitors of programmed cell death protein 1 and its ligand in postoperative chemotherapy for advanced colorectal cancer. نشریه علمی پژوهشی دانشگاه آزاد اسلامی, 1400; 13(1): -. doi: 10.47176/IJIC.13.1.3

Clinical efficacy and safety of inhibitors of programmed cell death protein 1 and its ligand in postoperative chemotherapy for advanced colorectal cancer

International Journal of Industrial Chemistry
دوره 13، شماره 1، خرداد 2022
نوع مقاله: research article
شناسه دیجیتال (DOI): 10.47176/IJIC.13.1.3
نویسندگان
Xin Shi* 1؛ Hongli Gao2؛ Qian Zhao3؛ Mengqi Zhuang2
1Department of Oncology, The Fourth People's Hospital of Jinan, Jinan 250031, Shandong, China
2Department of Oncology, The Fourth People's Hospital of Jinan, Jinan 250031, Shandong, China
3Department of Internal Medicine, The Fourth People's Hospital of Jinan, Jinan 250031, Shandong, China
چکیده
This research aimed to investigate the safety and efficacy of inhibitors of programmed cell death 1 and its ligand in the postoperative chemotherapy for advanced colorectal cancer. Patients with advanced colorectal cancer treated in our hospital from June 2019 to June 2021 were included (23 patients receiving Apatinib served as the control group and 28 patients receiving programmed cell death protein 1 inhibitor served as the experiment group). The safety and clinical efficacy of these two treatments were analyzed. The experiment group showed 7.1% of objective remission rate and 89.3% of disease control rate while the Apatinib group showed 8.7% of objective remission rate and 56.5% of disease control rate. The experiment group also showed higher progression-free survival (6.4 months) than Apatinib group (3.9 months) (P = 0.0209). Patients with no V-Ki-ras2 Kirsten ratsarcoma viral oncogene homolog wild-type, liver metastases and left-sided colon tumors could benefit from the experiment group. No significant difference was observed in adverse events between the 2 groups, and 8 patients (15.7%) in total had treatment-related grade 3 adverse event. To sum up, inhibitor of programmed cell death protein 1 and its ligand is efficacious for advanced colorectal cancer, with well safety and tolerance.
کلیدواژه‌ها
colorectal cancer؛ PD-1/PD-L1؛ apatinib؛ clinical efficacy؛ safety
آمار
تعداد مشاهده مقاله: 21


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب